{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:28:28Z","timestamp":1761949708089,"version":"build-2065373602"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Biological Regulation"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jbior.2019.100652","type":"journal-article","created":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T09:17:25Z","timestamp":1568539045000},"page":"100652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Insulin-like growth factor (IGF) signaling in T-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6740-4160","authenticated-orcid":false,"given":"Samuel","family":"Gusscott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5719-7276","authenticated-orcid":false,"given":"Francesco","family":"Tamiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-2080","authenticated-orcid":false,"given":"Vincenzo","family":"Giambra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P.","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbior.2019.100652_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jhep.2013.09.008","article-title":"A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma","volume":"60","author":"Abou-Alfa","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jbior.2019.100652_bib2","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ejca.2010.02.050","article-title":"HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene","volume":"46","author":"Aiello","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbior.2019.100652_bib3","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1182\/blood-2008-02-138172","article-title":"NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity","volume":"113","author":"Armstrong","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100652_bib4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1084\/jem.20040789","article-title":"Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells","volume":"200","author":"Barata","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jbior.2019.100652_bib5","first-page":"299","article-title":"Targeting the PI3K\/AKT\/mTOR signaling axis in children with hematologic malignancies","volume":"14","author":"Barrett","year":"2012","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jbior.2019.100652_bib6","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00280-014-2391-2","article-title":"Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial","volume":"73","author":"Becerra","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jbior.2019.100652_bib7","first-page":"1147","article-title":"Regulation of insulin-like growth factor I receptor gene expression by Sp1: physical and functional interactions of Sp1 at GC boxes and at a CT element","volume":"9","author":"Beitner-Johnson","year":"1995","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.jbior.2019.100652_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3747\/co.23.2806","article-title":"Targeting leukemia stem cells: which pathways drive self-renewal activity in T-cell acute lymphoblastic leukemia?","volume":"23","author":"Belmonte","year":"2016","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.jbior.2019.100652_bib9","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1517\/13543784.2011.558501","article-title":"Small molecule inhibitors of the IGF-1R\/IR axis for the treatment of cancer","volume":"20","author":"Buck","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jbior.2019.100652_bib10","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1158\/1535-7163.MCT-09-0499","article-title":"BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R\/IR","volume":"8","author":"Carboni","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jbior.2019.100652_bib11","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/stem.1463","article-title":"IGF-1-mediated osteoblastic niche expansion enhances long-term hematopoietic stem cell engraftment after murine bone marrow transplantation","volume":"31","author":"Caselli","year":"2013","journal-title":"Stem Cells"},{"key":"10.1016\/j.jbior.2019.100652_bib12","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1074\/jbc.M510204200","article-title":"Characterization of distinct Stat5b binding sites that mediate growth hormone-stimulated IGF-I gene transcription","volume":"281","author":"Chia","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbior.2019.100652_bib13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-416503","article-title":"Divergent effects of supraphysiologic Notch signals on leukemia stem cells and hematopoietic stem cells","volume":"121","author":"Chiang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100652_bib14","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1634\/theoncologist.2016-0220","article-title":"A randomized phase II study of linsitinib (OSI-906) versus topotecan in patients with relapsed small-cell lung cancer","volume":"21","author":"Chiappori","year":"2016","journal-title":"The Oncologist"},{"key":"10.1016\/j.jbior.2019.100652_bib15","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1182\/blood-2010-06-292300","article-title":"Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance","volume":"116","author":"Chiu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100652_bib16","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1158\/1078-0432.CCR-04-1070","article-title":"Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871","volume":"11","author":"Cohen","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbior.2019.100652_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pcl.2014.09.006","article-title":"Treatment of pediatric acute lymphoblastic leukemia","volume":"62","author":"Cooper","year":"2015","journal-title":"Pediatr. Clin. N. Am."},{"key":"10.1016\/j.jbior.2019.100652_bib18","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood-2006-06-030445","article-title":"Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia","volume":"109","author":"Cox","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100652_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0092-8674(89)90281-X","article-title":"Signal transmission by the insulin-like growth factors","volume":"59","author":"Czech","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.jbior.2019.100652_bib20","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1210\/endo.142.9.8400","article-title":"STAT5b is required for GH-induced liver IGF-I gene expression","volume":"142","author":"Davey","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.jbior.2019.100652_bib21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd917","article-title":"Structural biology of insulin and IGF1 receptors: implications for drug design","volume":"1","author":"De Meyts","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbior.2019.100652_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.gendis.2014.10.004","article-title":"Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance","volume":"2","author":"Denduluri","year":"2015","journal-title":"Genes Dis"},{"key":"10.1016\/j.jbior.2019.100652_bib23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cytogfr.2005.04.004","article-title":"Molecular interactions of the IGF system","volume":"16","author":"Denley","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jbior.2019.100652_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.3104","article-title":"Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R\/insulin receptor (IR) inhibitor in subjects with solid tumors","volume":"28","author":"Desai","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbior.2019.100652_bib25","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/nsb721","article-title":"Structure and autoregulation of the insulin-like growth factor 1 receptor kinase","volume":"8","author":"Favelyukis","year":"2001","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.jbior.2019.100652_bib26","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/endo.143.2.8641","article-title":"Regulation of IGF-I mRNA and signal transducers and activators of transcription-3 and -5 (Stat-3 and -5) by GH in C2C12 myoblasts","volume":"143","author":"Frost","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.jbior.2019.100652_bib27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ghir.2004.06.001","article-title":"Free insulin-like growth factors -- measurements and relationships to growth hormone secretion and glucose homeostasis","volume":"14","author":"Frystyk","year":"2004","journal-title":"Growth Hormone IGF Res."},{"key":"10.1016\/j.jbior.2019.100652_bib28","first-page":"1458","article-title":"Repression of Igf1 expression by Ezh2 prevents basal cell differentiation in the developing lung","volume":"142","author":"Galvis","year":"2015","journal-title":"Development"},{"key":"10.1016\/j.jbior.2019.100652_bib29","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/nm.2960","article-title":"NOTCH1 promotes T cell leukemia-initiating activity by RUNX-mediated regulation of PKC-\u03b8 and reactive oxygen species","volume":"18","author":"Giambra","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbior.2019.100652_bib30","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2014-10-609370","article-title":"Leukemia stem cells in T-ALL require active Hif1\u03b1 and Wnt signaling","volume":"125","author":"Giambra","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100652_bib31","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.stem.2018.08.018","article-title":"Epigenetic restoration of fetal-like IGF1 signaling inhibits leukemia stem cell activity","volume":"23","author":"Giambra","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jbior.2019.100652_bib32","doi-asserted-by":"crossref","first-page":"8247","DOI":"10.1073\/pnas.1431613100","article-title":"Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor","volume":"100","author":"Girnita","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbior.2019.100652_bib33","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1200\/JCO.2003.10.116","article-title":"Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience","volume":"21","author":"Goldberg","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbior.2019.100652_bib34","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1210\/en.2007-0608","article-title":"Conditional deletion of insulin-like growth factor-I in collagen type 1alpha2-expressing cells results in postnatal lethality and a dramatic reduction in bone accretion","volume":"148","author":"Govoni","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.jbior.2019.100652_bib35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1152\/physiolgenomics.00022.2007","article-title":"Disruption of insulin-like growth factor-I expression in type IIalphaI collagen-expressing cells reduces bone length and width in mice","volume":"30","author":"Govoni","year":"2007","journal-title":"Physiol. Genom."},{"key":"10.1016\/j.jbior.2019.100652_bib36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1158\/1078-0432.CCR-15-0588","article-title":"Clinical and translational results of a phase II, randomized trial of an anti-IGF-1r (cixutumumab) in women with breast cancer that progressed on endocrine therapy","volume":"22","author":"Gradishar","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbior.2019.100652_bib37","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature06933","article-title":"Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation","volume":"453","author":"Guo","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jbior.2019.100652_bib38","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.leukres.2012.02.013","article-title":"Notch-mediated repression of miR-223 contributes to IGF1R regulation in T-ALL","volume":"36","author":"Gusscott","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jbior.2019.100652_bib39","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.leukres.2012.02.013","article-title":"Notch-mediated repression of miR-223 contributes to IGF1R regulation in T-ALL","volume":"36","author":"Gusscott","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jbior.2019.100652_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161158","article-title":"IGF1R derived PI3K\/AKT signaling maintains growth in a subset of human T-cell acute lymphoblastic leukemias","volume":"11","author":"Gusscott","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jbior.2019.100652_bib41","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1182\/blood-2009-02-206722","article-title":"High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia","volume":"114","author":"Gutierrez","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100652_bib42","first-page":"T69","volume":"vol. 61","author":"Hakuno","year":"2018"},{"key":"10.1016\/j.jbior.2019.100652_bib43","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1158\/1078-0432.CCR-07-1118","article-title":"Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors","volume":"13","author":"Haluska","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbior.2019.100652_bib44","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-009-1083-9","article-title":"Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma","volume":"65","author":"Haluska","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jbior.2019.100652_bib45","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3892\/ijo.2016.3401","article-title":"miR-223 reverses the resistance of EGFR-TKIs through IGF1R\/PI3K\/Akt signaling pathway","volume":"48","author":"Han","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jbior.2019.100652_bib46","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1210\/endo.141.7.7550","article-title":"A targeted partial invalidation of the insulin-like growth factor I receptor gene in mice causes a postnatal growth deficit","volume":"141","author":"Holzenberger","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.jbior.2019.100652_bib47","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2015-02-627414","article-title":"Chemotherapy-only treatment effects on long-term neurocognitive functioning in childhood ALL survivors: a review and meta-analysis","volume":"126","author":"Iyer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100652_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027008","article-title":"MiR-223 suppresses cell proliferation by targeting IGF-1r","volume":"6","author":"Jia","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jbior.2019.100652_bib49","first-page":"472","article-title":"Regulation of IGF -1 signaling by microRNAs","volume":"5","author":"Jung","year":"2014","journal-title":"Front. Genet."},{"key":"10.1016\/j.jbior.2019.100652_bib50","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03772","article-title":"How IGF-1 activates its receptor","volume":"3","author":"Kavran","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.jbior.2019.100652_bib51","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.cell.2013.05.041","article-title":"The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability","volume":"153","author":"King","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jbior.2019.100652_bib52","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.ctrv.2014.07.004","article-title":"Can we unlock the potential of IGF-1R inhibition in cancer therapy?","volume":"40","author":"King","year":"2014","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.jbior.2019.100652_bib53","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.jbior.2019.100652_bib54","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1158\/1078-0432.CCR-10-1903","article-title":"High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy","volume":"17","author":"Litzenburger","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbior.2019.100652_bib55","first-page":"59","article-title":"Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)","volume":"75","author":"Liu","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.jbior.2019.100652_bib56","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa025406","article-title":"Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia","volume":"349","author":"L\u00f6wenberg","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbior.2019.100652_bib57","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.37.4355","article-title":"Phase I\/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group","volume":"30","author":"Malempati","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbior.2019.100652_bib58","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jbior.2019.100652_bib59","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1006\/mgme.1999.2958","article-title":"BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1","volume":"69","author":"Maor","year":"2000","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.jbior.2019.100652_bib60","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.canlet.2007.07.019","article-title":"Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations","volume":"257","author":"Maor","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jbior.2019.100652_bib61","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1084\/jem.20110121","article-title":"High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling","volume":"208","author":"Medyouf","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jbior.2019.100652_bib62","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1084\/jem.20110121","article-title":"High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling","volume":"208","author":"Medyouf","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jbior.2019.100652_bib63","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/jcp.21405","article-title":"Grb10\/Nedd4-mediated multiubiquitination of the insulin-like growth factor receptor regulates receptor internalization","volume":"216","author":"Monami","year":"2008","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jbior.2019.100652_bib64","doi-asserted-by":"crossref","first-page":"10100","DOI":"10.1158\/0008-5472.CAN-06-1684","article-title":"Heterodimerization of insulin-like growth factor receptor\/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib","volume":"66","author":"Morgillo","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbior.2019.100652_bib65","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.4155\/fmc.09.89","article-title":"Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor","volume":"1","author":"Mulvihill","year":"2009","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.jbior.2019.100652_bib66","doi-asserted-by":"crossref","first-page":"11118","DOI":"10.1158\/0008-5472.CAN-04-3841","article-title":"Insulin-like growth factor-I receptor\/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells","volume":"65","author":"Nahta","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbior.2019.100652_bib67","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrc3184","article-title":"Cancer stem cells: an evolving concept","volume":"12","author":"Nguyen","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbior.2019.100652_bib68","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jbior.2018.09.012","article-title":"IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: an update","volume":"71","author":"Oliveira","year":"2019","journal-title":"Advances in Biological Regulation"},{"key":"10.1016\/j.jbior.2019.100652_bib69","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1470-2045(09)70354-7","article-title":"Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study","volume":"11","author":"Olmos","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbior.2019.100652_bib70","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.exphem.2015.12.009","article-title":"Ezh2 regulates the Lin28\/let-7 pathway to restrict activation of fetal gene signature in adult hematopoietic stem cells","volume":"44","author":"Oshima","year":"2016","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.jbior.2019.100652_bib71","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1182\/blood-2011-11-389841","article-title":"Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine","volume":"119","author":"Pabst","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100652_bib72","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/cncr.28728","volume":"120","author":"Pappo","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jbior.2019.100652_bib73","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrc3215","article-title":"The insulin and insulin-like growth factor receptor family in neoplasia: an update","volume":"12","author":"Pollak","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbior.2019.100652_bib74","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc1387","article-title":"Insulin-like growth factors and neoplasia","volume":"4","author":"Pollak","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbior.2019.100652_bib75","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood-2016-10-696039","article-title":"Therapeutic targeting of acute myeloid leukemia stem cells","volume":"129","author":"Pollyea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100652_bib76","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1158\/1078-0432.CCR-14-0303","article-title":"A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors","volume":"21","author":"Puzanov","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbior.2019.100652_bib77","doi-asserted-by":"crossref","first-page":"29501","DOI":"10.18632\/oncotarget.15704","article-title":"Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy","volume":"8","author":"Qu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbior.2019.100652_bib78","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1002\/cncr.27459","article-title":"A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors","volume":"118","author":"Reidy-Lagunes","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jbior.2019.100652_bib79","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1210\/en.2004-0173","article-title":"Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53","volume":"145","author":"Rubinstein","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.jbior.2019.100652_bib80","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1210\/endo.142.9.8365","article-title":"GH regulation of IGF-I and suppressor of cytokine signaling gene expression in C2C12 skeletal muscle cells","volume":"142","author":"Sadowski","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.jbior.2019.100652_bib81","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nbt.1607","article-title":"Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML","volume":"28","author":"Saito","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jbior.2019.100652_bib82","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ghir.2009.08.001","article-title":"Transcription factor E2F1 is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene","volume":"20","author":"Schayek","year":"2010","journal-title":"Growth Hormone IGF Res."},{"key":"10.1016\/j.jbior.2019.100652_bib83","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/annonc\/mdr574","article-title":"Phase II study of figitumumab in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02)","volume":"23","author":"Schmitz","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbior.2019.100652_bib84","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/j.ejca.2013.06.010","article-title":"An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours","volume":"49","author":"Schoffski","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbior.2019.100652_bib85","doi-asserted-by":"crossref","first-page":"19288","DOI":"10.1016\/S0021-9258(18)54996-6","article-title":"Insulin and insulin-like growth factor-1 binding specificity is determined by distinct regions of their cognate receptors","volume":"266","author":"Schumacher","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbior.2019.100652_bib86","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cas.12906","article-title":"Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1\/insulin receptor selectivity","volume":"107","author":"Schwartz","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jbior.2019.100652_bib87","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ijc.10537","article-title":"Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells","volume":"101","author":"Scotlandi","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbior.2019.100652_bib88","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1158\/0008-5472.CAN-07-6364","article-title":"Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis","volume":"68","author":"Sehat","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbior.2019.100652_bib89","first-page":"3604","article-title":"Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts","volume":"14","author":"Sell","year":"1994","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jbior.2019.100652_bib90","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1073\/pnas.96.12.7088","article-title":"Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice","volume":"96","author":"Sjogren","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbior.2019.100652_bib91","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1042\/bj2700383","article-title":"Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells","volume":"270","author":"Soos","year":"1990","journal-title":"Biochem. J."},{"issue":"Pt 2","key":"10.1016\/j.jbior.2019.100652_bib92","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1042\/bj2900419","article-title":"Purified hybrid insulin\/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity","volume":"290","author":"Soos","year":"1993","journal-title":"Biochem. J."},{"key":"10.1016\/j.jbior.2019.100652_bib93","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fonc.2014.00108","article-title":"Targeting the PI3K\/mTOR pathway in pediatric hematologic malignancies","volume":"4","author":"Tasian","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.jbior.2019.100652_bib94","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1182\/blood-2010-08-300343","article-title":"Notch1 inhibition targets the leukemia-initiating cells in a Tal1\/Lmo2 mouse model of T-ALL","volume":"118","author":"Tatarek","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100652_bib95","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1200\/JCO.2009.23.6745","article-title":"Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1","volume":"27","author":"Tolcher","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbior.2019.100652_bib96","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1101\/gad.1897910","article-title":"Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes","volume":"24","author":"Tremblay","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.jbior.2019.100652_bib97","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cell.2014.05.049","article-title":"Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia","volume":"158","author":"Trimarchi","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jbior.2019.100652_bib98","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1128\/MCB.15.7.3516","article-title":"Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression","volume":"15","author":"Werner","year":"1995","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jbior.2019.100652_bib99","doi-asserted-by":"crossref","first-page":"8318","DOI":"10.1073\/pnas.93.16.8318","article-title":"Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene","volume":"93","author":"Werner","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbior.2019.100652_bib100","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10911-008-9104-6","article-title":"IGF-1 receptor inhibitors in clinical trials\u2014early lessons","volume":"13","author":"Weroha","year":"2008","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"10.1016\/j.jbior.2019.100652_bib101","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10911-008-9104-6","article-title":"IGF-1 receptor inhibitors in clinical trials--early lessons","volume":"13","author":"Weroha","year":"2008","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"10.1016\/j.jbior.2019.100652_bib102","doi-asserted-by":"crossref","first-page":"E393","DOI":"10.1152\/ajpendo.00389.2003","article-title":"In vivo regulation of growth hormone-stimulated gene transcription by STAT5b","volume":"286","author":"Woelfle","year":"2004","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.jbior.2019.100652_bib103","doi-asserted-by":"crossref","first-page":"22696","DOI":"10.1074\/jbc.M301362200","article-title":"Acute control of insulin-like growth factor-I gene transcription by growth hormone through Stat5b","volume":"278","author":"Woelfle","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbior.2019.100652_bib104","doi-asserted-by":"crossref","first-page":"51261","DOI":"10.1074\/jbc.M309486200","article-title":"Mechanisms of growth hormone (GH) action. Identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation","volume":"278","author":"Woelfle","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbior.2019.100652_bib105","first-page":"4384","article-title":"Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors","volume":"63","author":"Wu","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbior.2019.100652_bib106","doi-asserted-by":"crossref","first-page":"7324","DOI":"10.1073\/pnas.96.13.7324","article-title":"Normal growth and development in the absence of hepatic insulin-like growth factor I","volume":"96","author":"Yakar","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbior.2019.100652_bib107","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1038\/sj.onc.1210474","article-title":"The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma","volume":"26","author":"Yuen","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.jbior.2019.100652_bib108","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3324\/haematol.2011.059030","article-title":"The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia","volume":"97","author":"Zuurbier","year":"2012","journal-title":"Haematologica"}],"container-title":["Advances in Biological Regulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492619300739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492619300739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:25:52Z","timestamp":1761949552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212492619300739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":108,"alternative-id":["S2212492619300739"],"URL":"https:\/\/doi.org\/10.1016\/j.jbior.2019.100652","relation":{},"ISSN":["2212-4926"],"issn-type":[{"type":"print","value":"2212-4926"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insulin-like growth factor (IGF) signaling in T-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Advances in Biological Regulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbior.2019.100652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100652"}}